Biohaven Pharmaceutical Holding Co Ltd. (BHVN) is a publicly traded company in the Unknown sector. Across all available filings, 23 corporate insiders have executed 754 transactions totaling $417.2M, demonstrating a bullish sentiment with $2.9M in net insider flow. The most recent transaction on Jan 5, 2026 involved a transaction of 2,500 shares valued at $0.
No significant insider buying has been recorded for BHVN in the recent period.
No significant insider selling has been recorded for BHVN in the recent period.
Based on recent SEC filings, insider sentiment for BHVN is bullish with an Insider Alignment Score of 50/100 and a net flow of $2.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Biohaven Pharmaceutical Holding Co Ltd. (BHVN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 23 insiders are actively trading BHVN stock, having executed 754 transactions in the past 90 days. The most active insider is John W. Childs (Executive), who has made 55 transactions totaling $610.6M.
Get notified when executives and directors at BHVN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | C. Clark George | VP, Chief Accounting Officer | Option Exercise | 2,500 | $N/A | $0 | |
| Jan 5, 2026 | C. Clark George | VP, Chief Accounting Officer | Payment | 1,117 | $9.93 | $11.1K | |
| Jan 5, 2026 | C. Clark George | VP, Chief Accounting Officer | Option Exercise | 2,500 | $N/A | $0 | |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Option Exercise | 4,750 | $N/A | $0 | |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Payment | 2,381 | $9.93 | $23.6K | |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Option Exercise | 4,750 | $N/A | $0 | |
| Jan 5, 2026 | Coric Vlad | Executive | Option Exercise | 14,250 | $N/A | $0 | |
| Jan 5, 2026 | Coric Vlad | Executive | Payment | 7,430 | $9.93 | $73.8K | |
| Jan 5, 2026 | Coric Vlad | Executive | Option Exercise | 14,250 | $N/A | $0 | |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Option Exercise | 4,250 | $N/A | $0 | C-Suite |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Payment | 2,594 | $9.93 | $25.8K | C-Suite |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Option Exercise | 4,250 | $N/A | $0 | C-Suite |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Option Exercise | 3,750 | $N/A | $0 | |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Payment | 1,956 | $9.93 | $19.4K | |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Option Exercise | 3,750 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Disposition(D) | 19 | $988.0M | 68.4% |
Purchase(P) | 68 | $210.1M | 14.5% |
Sale(S) | 310 | $207.2M | 14.3% |
Exercise(M) | 196 | $23.9M | 1.7% |
Payment(F) | 62 | $12.9M | 0.9% |
Award(A) | 12 | $2.0M | 0.1% |
Other(J) | 35 | $0 | 0.0% |
Gift(G) | 45 | $0 | 0.0% |
Discretionary(I) | 2 | $0 | 0.0% |
Conversion(C) | 5 | $0 | 0.0% |
Insider activity at Biohaven Pharmaceutical Holding Co Ltd. shows mixed signals across all time. While $210.1M in purchases indicates some executive confidence,$207.2M in sales balances the picture, resulting in a modest net flow of $2.9M.23 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, John W. Childs, has transacted $610.6M during this period.